Overview

Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms

Status:
Terminated
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
To identify the maximum tolerated dose (MTD) of oral azacitidine on different treatment schedules in Japanese subjects with hematological neoplasms
Phase:
Phase 1
Details
Lead Sponsor:
Celgene Corporation
Treatments:
Azacitidine